Eli Lilly receives CDSCO approval for donanemab, a new Alzheimer's treatment targeting early symptomatic stages of the ...

A new study shows that lecanemab, an amyloid-clearing Alzheimer’s therapy, does not improve the brain’s waste-removal network ...

Investing.com -- Eli Lilly and Company (India) Pvt. has received marketing approval from India’s Central Drugs Standard Control Organization for donanemab, a medication used to treat Alzheimer’s ...

In a new study, scientists discovered two FDA-approved cancer drugs that could also be effective at combatting one well-known ...

A new study has identified three existing medications that could be repurposed to treat or prevent Alzheimer's disease.The ...

Scientists hail ‘very exciting’ findings that explain why Alzheimer’s patients forget their loved ones, and say drugs are ...

Scientists tested the substance on rats with positive results and are now seeking partnerships with pharmaceutical companies to conduct clinical trials. A research team at the Federal University of AB ...

Anavex Life Sciences (AVXL) stock falls as the company faces a potential failure to win EU approval for its Alzheimer’s ...

A new study, funded by Alzheimer’s Society, has identified three existing medications that could be repurposed to treat or ...

The roadmap to fighting Alzheimer’s disease is a matter of updating government policy to match the current science.

Researchers found that lecanemab, the Alzheimer’s drug designed to clear amyloid-β plaques, does not improve the brain’s waste clearance system in the short term.